Survival outcome of adjuvant chemotherapy and high 21-gene recurrence score in early-stage breast cancer
{{output}}
Among patients with early-stage breast cancer and a high 21-gene recurrence score (RS) ≥ 26, it remains unclear on whether those with RS 26-30 would benefit from chemotherapy with a comparable magnitude as those with RS > 30. In addition, RS > 30 as an indepe... ...
